AltheaDx News - Bringing Cancer Diagnostics into Clinical Use


April 15, 2008	AltheaDx Named Affymetrix Authorized Service Provider
AltheaDx Will Offer Affymetrix Technology as Part of a Complete Biomarker Discovery and Development Platform Full Story \| 439 views
April 15, 2008	AltheaDx Appoints Vice President of Business Development, Sales and Marketing
AltheaDx, Inc. announced today that Cyrus Mirsaidi has been appointed Vice President of Business Development, Sales and Marketing, reporting directly to the CEO. Full Story \| 492 views
April 14, 2008	Poniard Pharmaceuticals and AltheaDx Sign Agreement - Poniard to investigate molecular signatures for platinum resistance
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has selected AltheaDx, Inc.'s Express Pathway program to identify molecular signatures which may be correlated to platinum resistance. Full Story \| 338 views
March 04, 2008	Althea Diagnostics Board of Directors Appoints Industry Veteran CEO
Althea Diagnostics Incorporated announced today that David Macdonald has been appointed the Chief Executive Officer of the firm. Full Story \| 375 views
February 25, 2008	Althea Technologies Announces the Spin-out of an Independent Company, Althea Diagnostics
Althea Technologies, Inc., a leading provider of innovative technologies and pharmaceutical services, announced today that it has spun-out an independent company to commercialize its breakthrough genetic testing technology through a variety of laboratory services and gene expression products for use in monitoring and managing cancer treatment. Full Story \| 288 views
October 02, 2007	Althea Technologies Expands Collaboration with BiPar Sciences
Althea Technologies, Inc., today announced the expansion of a collaboration with BiPar Sciences, Inc. to provide pharmacogenomic support for BiPar�s drug development programs in oncology. Full Story \| 243 views
February 20, 2007	Althea Technologies Announces the Development of a Diagnostic Capable of Differentiating Multiple Forms of Childhood Cancer
Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today the development of a molecular diagnostic capable of clearly differentiating various types of childhood cancers resulting from collaborative efforts between Althea and the U.S. National Cancer Institute (NCI). Full Story \| 248 views
February 01, 2007	Althea Technologies and Blueshift Biotechnologies Combine Technologies for High Throughput, Gene Expression Screening
Althea Technologies, Inc. and Blueshift Biotechnologies announced today that Althea has received a SBIR award from the National Human Genome Research Institute to explore the potential for practical high throughput and low cost gene expression analysis. Full Story \| 247 views